RGD Reference Report - Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant.

Authors: Peles, Einat  Kim, Yuli  Sason, Anat  Adelson, Miriam  Levran, Orna 
Citation: Peles E, etal., Drug Alcohol Depend. 2023 Sep 1;250:110903. doi: 10.1016/j.drugalcdep.2023.110903. Epub 2023 Jul 22.
RGD ID: 401977581
Pubmed: PMID:37531661   (View Abstract at PubMed)
DOI: DOI:10.1016/j.drugalcdep.2023.110903   (Journal Full-text)


BACKGROUND: Variants in the delta opioid receptor gene, OPRD1, were associated with opioid use disorder and response to treatment. The study goal was to assess whether OPRD1 variants predict survival and retention in methadone maintenance treatment (MMT).
METHODS: Retention and survival time since admission (June 1993 - June 2022) until leaving treatment (for retention), or at the end of follow-up (Dec 2022) (for retention and survival) were analyzed in 488 patients. Vital data was taken from a national registry. Predictors were estimated using Kaplan-Meier and Cox regression models.
RESULTS: Longer retention and survival were found for carriers of the T allele of SNP rs204076. This SNP is associated with OPRD1 expression in cortex (GTEx). Carriers of the T allele (n = 251) survived longer compared to non-carriers (24.7 vs. 20.2 years, p = 0.005) and had longer retention (11.2 vs. 8.8 years, p = 0.04). Multivariate analysis identified the T allele as an independent predictor of longer survival time (p = 0.003) and retention (p = 0.009). Additional predictors for survival were no benzodiazepine use after one year in MMT, no hepatitis C, <20 years of opioid usage, and admission at age < 30. Additional predictors for longer retention were no use of other drugs except opioids on admission, and no drugs at one year, as well as methadone dose >= 100mg/d at one year and axis I & II DSM-5 psychiatric diagnosis.
CONCLUSIONS: The OPRD1 SNP rs204076 and non-genetic predictors contribute to survival time and retention in MMT patients.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
OPRD1Humanopiate dependence treatmentIAGP associated with methadone treatment and DNA:SNP:intron (rs204076) (human)RGD 
Oprd1Ratopiate dependence treatmentISOOPRD1 (Homo sapiens)associated with methadone treatment and DNA:SNP:intron (rs204076) (human)RGD 
Oprd1Mouseopiate dependence treatmentISOOPRD1 (Homo sapiens)associated with methadone treatment and DNA:SNP:intron (rs204076) (human)RGD 

Phenotype Annotations    Click to see Annotation Detail View

Manual Human Phenotype Annotations - RGD

Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
OPRD1HumanAddictive cocaine use amelioratesIAGP associated with methadone treatment and DNA:SNP:intron (rs204076) (human)RGD 
OPRD1HumanAmeliorated by exposure to medication  IAGP associated with opiate dependence more ...RGD 
OPRD1HumanPositive methadone plasma/serum test  IAGP associated with opiate dependence more ...RGD 
Objects Annotated

Genes (Rattus norvegicus)
Oprd1  (opioid receptor, delta 1)

Genes (Mus musculus)
Oprd1  (opioid receptor, delta 1)

Genes (Homo sapiens)
OPRD1  (opioid receptor delta 1)


Additional Information